Celsis IVT Announces Symposia and Poster Presentations at the 18th North American Regional ISSX Meeting

  • Email
  • Print

Chicago, Ill. – October 11, 2012 – Celsis In Vitro Technologies (Celsis IVT), the pioneer and leader in hepatocyte technology, will host an industry-supported symposium as well as several poster presentations at the 18th North American Regional ISSX Meeting to be held on October 14-18, 2012 at the Hilton Anatole Hotel in Dallas, Texas. Meeting attendees are encouraged to speak with Celsis IVT about its cryopreserved products, patented LiverPoolTM human hepatocytes, and Custom-Cell™ products for in vitro research. Industry-Supported Symposium Will Address New Data Related to Human Cell Systems

Timothy Moeller, Scientific Advisor, Celsis IVT and J. Matthew Hutzler, Ph.D., Senior Principal Scientist, Boehringer-Ingelheim Pharmaceuticals, Inc. will host the industry-supported symposium Characterization of Aldehyde Oxidase in Human Cell Systems on Tuesday, October 16 from 7:45 a.m. to 8:45 a.m. in Room Cortez AB. The symposium will present new data to address sources of variation in aldehyde oxidase activity, including inter-donor variation, fresh versus cryopreserved hepatocytes activity and induction data with prototypical inducers.

Additionally, Celsis and Boehringer-Ingelheim’s collaborative poster presentation, Assessment of the Stability of Aldehyde Oxidase Activity in Fresh and Cryopreserved Human Hepatocytes, will be highlighted during the ISSX symposium I: Non-P450 dependent Oxidation Reactions on Monday, October 15 from 2:00 p.m. to 4:00 p.m.

Multiple Poster Presentations Present New Findings Related to Hepatocyte Use

Various poster presentations from Celsis and its collaborators will highlight new findings related to the use of cryopreserved human hepatocytes for in vitro research. The poster presentations include:

  • Assessment of the Stability of Aldehyde Oxidase Activity in Fresh and Cryopreserved Human Hepatocytes (in collaboration with Boehringer-Ingelheim Pharmaceuticals)
  • Transcript Regulation of 18 ADME Genes by Prototypical Inducers in Human Hepatocytes (in collaboration with Affymetrix)
  • Use of Hepatocyte and Kupffer Cell Co-Culture Models in Assessment of Cytochrome P450 Metabolism
  • Use of Cold Compounds and High Resolution Mass Spectrometry to Quickly Characterize Drug Update in Cryopreserved Human Hepatocytes (in collaboration with MicroConstants)
  • Demographic Differences in Age, BMI, Gender and Ethnicity of Phase I and Phase II Enzyme Activities in Cryopreserved Human Hepatocytes Your Research, Your Way

In addition to offering the world’s largest inventory of cryopreserved hepatocytes, Celsis IVT can also fill any custom order by providing pooled or specific animal products to meet unique research requirements. Celsis’ quality certification process ensures lot-to-lot consistency, high viability and targeted activity levels. To learn more, visit www.celsisivt.com.

About Celsis IVT

Celsis IVT, a subsidiary of Celsis International Ltd, is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development. Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization. Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research. Celsis IVT's patented LiverPool products; cryoplateable hepatocytes (the world's largest inventory); and other ADMET research tools are available worldwide.

About ISSX

Headquartered in Washington, DC, the International Society for the Study of Xenobiotics (ISSX) is the premier scientific organization for researchers interested in the metabolism and disposition of xenobiotics. Founded in 1981, ISSX conducts cutting-edge scientific meetings worldwide.

Media Contacts
Cindy Lieberman – Corporate Marketing
Celsis International
T +1 312 476 1200
clieberman@celsis.com

  • <<
  • >>